Scienture Holdings Inc (NASDAQ: SCNX) is a specialty pharmaceutical company focused on the commercialization and development of drug products targeting Cardiovascular (CVS) and Central Nervous System (CNS) diseases. Revenue is generated through product sales, with subsidiary IPS operating as a licensed wholesaler of brand, generic, and non-drug products that recognizes revenue at the time orders are invoiced and filled. Scienture LLC, acquired on July 25, 2024, launched its first commercial product for hypertension and received FDA approval for SCN-102 in March 2025, commencing commercialization in Q3 2025. The company reported a net loss from continuing operations of $41,512,264 for the year ended December 31, 2025, compared to a net loss of $15,803,908 for the year ended December 31, 2024. The development pipeline includes SCN-104 (opioid overdose, drug-device combination injection pen), SCN-106, and SCN-107, targeting migraine, thrombosis, pain, and related disorders, with regulatory approvals projected between 2027 and 2029 per the 10-K filed March 30, 2026.

Revenue model

Product sales through IPS, a licensed pharmaceutical wholesaler that recognizes revenue at point of order fulfillment under ASC 606. Commercial revenue from Scienture LLC's approved specialty pharmaceutical products began in Q3 2025 with SCN-102.

Products and services

SCN-102: FDA-approved hypertension treatment, commercialized Q3 2025. SCN-104: opioid overdose treatment, drug-device combination injection pen, in commercialization process as of the 10-K filed March 30, 2026. Pipeline candidates SCN-106 and SCN-107 targeting migraine, thrombosis, pain, and related CNS/CVS disorders remain in clinical or preclinical development.

Customers and end markets

End markets are cardiovascular disease and central nervous system disorders, including hypertension, opioid overdose, migraine, thrombosis, and pain. IPS serves customers as a licensed wholesaler of brand, generic, and non-drug pharmaceutical products. Specific customer names and concentration data are not disclosed in the filing excerpts.

Value-chain role

Drug developer and commercializer: conducts clinical and preclinical development, seeks FDA regulatory approval, and sells approved products to market. IPS subsidiary operates as a licensed pharmaceutical wholesaler. Intellectual property is assigned to the company through employee and contractor agreements.

Geographic exposure

United States, based on FDA regulatory pathway references and U.S. state and federal privacy law disclosures. No international revenue breakdown is provided in the filing excerpts.

Source: SEC 10-K, filed 2026-03-30

Industry: Pharmaceutical Preparations Peers: Amazon.com Inc Fovea Jewelry Holdings Ltd. Legacy IMBDS, Inc. Starco Brands Inc KIDPIK CORP. Scientific Energy Inc SHARING SERVICES GLOBAL Corp SHONGHOYA INTERNATIONAL GROUP INC.